BackCelyad Oncology Overview

Celyad Oncology Inventory

Latest inventory for CYAD: $0.

Get informed when a big investor buys or sells

+ Follow
Inventory
$0.00

Peer trimmed avg / median

Loading

Celyad Oncology Inventory History

Loading

Celyad Oncology vs. peers: Inventory Comparison

Loading

Celyad Oncology Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Celyad Oncology (CYAD) FAQ

Celyad Oncology (CYAD) currently reports a inventory of $0 as of June 2024. In the prior-year period, the figure was $0. Use the charts on this page to explore Celyad Oncology's inventory history and peer comparisons.

Celyad Oncology's inventory changed from $0 to $0 (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Celyad Oncology reported $0 in inventory as of June 2024. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current inventory of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Celyad Oncology, and consider following CYAD for alerts when major investors trade the stock.

Celyad Oncology is classified in the Healthcare sector. On inventory, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYAD with unrelated industries.